络氨酸激酶抑制剂TKI治疗脑转移患者意义.pptVIP

Eur Respir J SCI：5.9分 PS 0：5.8%，1：58.8%；2：29.4% 厄洛替尼 1L：58.8%；2L：29.4%；3L：11.8% * * The cumulative incidence curves of CNS progression for each group are shown in Fig. 1. The cumulative risk of CNS progression at 6, 12, and 24 months was 1%, 6%, and 21%, respectively, in the EGFR-TKI group, and 7%, 19%, and32% in the chemotherapy group (P ? 0.026, Fig. 1A). When the analysis was narrowed to only those 119 patients without preexisting brain metastases, the 6-, 12- and 24-month cumulative rates of CNS progression were 1%, 3%, and 15% in the EGFR-TKI group, compared with corresponding rates of 7%, 17%, and 30% in the chemotherapy group (P? 0.032, Fig. 1B) * The cumulative incidence curves of CNS progression for each group are shown in Fig. 1. The cumulative risk of CNS progression at 6, 12, and 24 months was 1%, 6%, and 21%, respectively, in the EGFR-TKI group, and 7%, 19%, and32% in the chemotherapy group (P ? 0.026, Fig. 1A). When the analysis was narrowed to only those 119 patients without preexisting brain metastases, the 6-, 12- and 24-month cumulative rates of CNS progression were 1%, 3%, and 15% in the EGFR-TKI group, compared with corresponding rates of 7%, 17%, and 30% in the chemotherapy group (P? 0.032, Fig. 1B) * The cumulative incidence curves of CNS progression for each group are shown in Fig. 1. The cumulative risk of CNS progression at 6, 12, and 24 months was 1%, 6%, and 21%, respectively, in the EGFR-TKI group, and 7%, 19%, and32% in the chemotherapy group (P ? 0.026, Fig. 1A). When the analysis was narrowed to only those 119 patients without preexisting brain metastases, the 6-, 12- and 24-month cumulative rates of CNS progression were 1%, 3%, and 15% in the EGFR-TKI group, compared with corresponding rates of 7%, 17%, and 30% in the chemotherapy group (P? 0.032, Fig. 1B) * The cumulative incidence curves of CNS progression for each group are shown in Fig. 1. The cumulative risk of CNS progression at 6, 12, and 24 months was 1%, 6%, and 21%, respe